MX2022011804A - Uso de agentes para el tratamiento de condiciones respiratorias. - Google Patents

Uso de agentes para el tratamiento de condiciones respiratorias.

Info

Publication number
MX2022011804A
MX2022011804A MX2022011804A MX2022011804A MX2022011804A MX 2022011804 A MX2022011804 A MX 2022011804A MX 2022011804 A MX2022011804 A MX 2022011804A MX 2022011804 A MX2022011804 A MX 2022011804A MX 2022011804 A MX2022011804 A MX 2022011804A
Authority
MX
Mexico
Prior art keywords
agents
treatment
respiratory conditions
subject
compound
Prior art date
Application number
MX2022011804A
Other languages
English (en)
Inventor
Stephen Jay Kanes
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2022011804A publication Critical patent/MX2022011804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan métodos para tratar un síntoma de una condición respiratoria o una enfermedad asociada con un coronavirus, en un sujeto, que comprenden administrar al sujeto una cantidad efectiva de un agente seleccionado del grupo que consiste en el Compuesto 1 y el Compuesto 2, o una sal farmacéuticamente aceptable de los mismos.
MX2022011804A 2020-03-25 2021-03-24 Uso de agentes para el tratamiento de condiciones respiratorias. MX2022011804A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062994805P 2020-03-25 2020-03-25
US202062994803P 2020-03-25 2020-03-25
US202063000415P 2020-03-26 2020-03-26
US202063000418P 2020-03-26 2020-03-26
US202063006672P 2020-04-07 2020-04-07
US202063006671P 2020-04-07 2020-04-07
US202063063780P 2020-08-10 2020-08-10
US202063063803P 2020-08-10 2020-08-10
PCT/US2021/024010 WO2021195297A1 (en) 2020-03-25 2021-03-24 Use of agents for treatment of respiratory conditions

Publications (1)

Publication Number Publication Date
MX2022011804A true MX2022011804A (es) 2023-03-09

Family

ID=75478347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011804A MX2022011804A (es) 2020-03-25 2021-03-24 Uso de agentes para el tratamiento de condiciones respiratorias.

Country Status (15)

Country Link
US (2) US20230346801A1 (es)
EP (1) EP4125921A1 (es)
JP (1) JP2023519241A (es)
KR (1) KR20220157426A (es)
CN (1) CN115551514A (es)
AU (1) AU2021241622A1 (es)
BR (1) BR112022019085A2 (es)
CA (1) CA3176854A1 (es)
CL (1) CL2022002592A1 (es)
CO (1) CO2022013777A2 (es)
IL (1) IL296645A (es)
MX (1) MX2022011804A (es)
PE (1) PE20221911A1 (es)
TW (2) TW202202146A (es)
WO (2) WO2021195301A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298436B1 (en) 2012-01-23 2024-03-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI3224269T1 (sl) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
CN110088091A (zh) 2016-08-23 2019-08-02 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
WO2022067044A1 (en) * 2020-09-25 2022-03-31 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
WO2022115381A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Onc. Compositions and methods for treating cns disorders cross reference to related application
WO2023164387A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024020953A1 (zh) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515779A (en) 1999-04-29 2003-11-28 Purdue Pharma Ltd 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
IL298436B1 (en) 2012-01-23 2024-03-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3957309A1 (en) 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
IL310501A (en) 2012-12-18 2024-03-01 Washington University St Louis Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
RS60420B1 (sr) 2013-04-17 2020-07-31 Sage Therapeutics Inc 19-nor neuroaktivni steroidi za metode lečenja
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RU2754534C2 (ru) 2013-07-19 2021-09-03 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их использование
DK3488852T3 (da) 2013-08-23 2021-02-01 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) * 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016061537A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN107404877A (zh) 2014-10-16 2017-11-28 萨奇治疗股份有限公司 靶向cns 障碍的组合物和方法
SI3224269T1 (sl) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2017087864A1 (en) 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
RU2022102537A (ru) 2016-03-08 2022-03-30 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
AU2017297375B2 (en) 2016-07-11 2022-09-15 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
CN110088091A (zh) 2016-08-23 2019-08-02 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
IL303250A (en) 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
JP7382326B2 (ja) 2017-12-22 2023-11-16 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害の処置のための組成物および方法
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
CA3090724A1 (en) 2018-02-11 2019-08-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
US20210205329A1 (en) * 2018-05-21 2021-07-08 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
EP3806863A1 (en) 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
US20210177805A1 (en) * 2018-08-22 2021-06-17 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2020185710A1 (en) * 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor

Also Published As

Publication number Publication date
KR20220157426A (ko) 2022-11-29
CO2022013777A2 (es) 2022-10-11
WO2021195301A1 (en) 2021-09-30
WO2021195297A1 (en) 2021-09-30
IL296645A (en) 2022-11-01
JP2023519241A (ja) 2023-05-10
CA3176854A1 (en) 2021-09-30
BR112022019085A2 (pt) 2023-01-31
AU2021241622A1 (en) 2022-10-20
US20230346801A1 (en) 2023-11-02
PE20221911A1 (es) 2022-12-23
TW202202146A (zh) 2022-01-16
TW202143977A (zh) 2021-12-01
CL2022002592A1 (es) 2023-04-21
CN115551514A (zh) 2022-12-30
EP4125921A1 (en) 2023-02-08
US20230414636A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE543492T1 (de) Behandlung von lungenkrebs
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
SE0000601D0 (sv) Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
MX2022011278A (es) Metodo para el tratamiento de afecciones asociadas a covid-19.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.